Do you have the same question? Follow this Question
Mar 20, 2025 - 01:53 PM
We’ve provided several answers to questions related to Invega Sustenna Injection (Paliperidone Palmitate) , see some other helpful Q&A related to this product.
Question: How is Invega Sustenna administered?
Answer: Invega Sustenna is administered by injection into the deltoid or gluteal muscle once monthly by a healthcare provider. This long-acting injectable form ensures consistent medication levels, improving adherence and symptom control.
Question: What is the PubChem CID for the active ingredient?
Answer: The PubChem CID for the active ingredient is 115237. This identifier allows researchers and healthcare professionals to easily access detailed chemical information about the compound, facilitating further study and understanding.
Question: What is the bioavailability of this medication?
Answer: The bioavailability of this medication is 28%. Bioavailability is crucial as it indicates the percentage of the drug that enters the bloodstream and is available to have an active effect, influencing the effectiveness of the medication.
View all Invega Sustenna Injection (Paliperidone Palmitate) Questions & Answers
